International AIDS Society global scientific strategy: towards an HIV cure 2016

Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in developing a cure for HIV infection. The International AIDS Society convened a group of international experts to develop a scientific strategy for research towards an HIV cure. This Perspective summarizes the group's strategy.

Richard Jefferys | David Margolis | Jintanat Ananworanich | Monique Nijhuis | Brigitte Autran | Galit Alter | Sarah Palmer | Douglas Richman | Hans-Peter Kiem | Nir Eyal | Joseph D Tucker | Guido Silvestri | Ying-Ru Lo | Daniel Kuritzkes | Sarah Fidler | D. Richman | R. Walensky | Zhiwei Chen | G. Henderson | D. Kuritzkes | I. Wilson | J. van Lunzen | B. Autran | S. Lewin | J. Lifson | D. Douek | J. Ananworanich | J. Siliciano | J. Mellors | N. Eyal | J. McCune | G. Alter | T. Henrich | M. Ott | G. Silvestri | B. Spire | S. Deeks | J. Zack | H. Kiem | P. Cannon | É. Cohen | M. Benkirane | D. Persaud | M. Tolstrup | J. Singh | D. Barouch | J. Tucker | S. Eholie | R. Jefferys | N. Chomont | K. Moodley | M. Nijhuis | A. Sáez-Cirión | F. Barré-Sinoussi | S. Palmer | Y. Lo | Nicolas Chomont | Martin Tolstrup | Steven G Deeks | Ira Wilson | J. Auerbach | Cynthia I. Grossman | S. Fidler | Bruno Spire | Deborah Persaud | Jerome Singh | Asier Saez-Cirion | Melanie Ott | Sharon R Lewin | Paula Cannon | Joseph McCune | S. Valente | G. Behrens | Dan H Barouch | Zhiwei Chen | P. Newman | Marina Cavazzana | Giulio Maria Corbelli | Jan van Lunzen | Monsef Benkirane | Anna Laura Ross | Daniel Douek | Jeffrey D Lifson | John Mellors | Françoise Barre-Sinoussi | Judith Auerbach | Georg Behrens | Éric A Cohen | Serge Eholié | Laurindo Garcia | Cynthia Grossman | Gail Henderson | Timothy J Henrich | Keymanthri Moodley | Peter A Newman | Moses Supercharger Nsubuga | Matthew Sharp | Janet Siliciano | Jeffrey Taylor | Susana Valente | Rochelle Walensky | Jerome Zack | G. Corbelli | A. Ross | M. Cavazzana | D. Margolis | M. Nsubuga | L. Garcia | M. Sharp | Jeffrey Taylor | J. Singh | J. Singh

[1]  M. Lederman,et al.  Interleukin-7 promotes HIV persistence during antiretroviral therapy. , 2013, Blood.

[2]  J. Church.  Depletion of Latent HIV-1 Infection in Vivo: A Proof-of-Concept Study , 2006, Pediatrics.

[3]  P. Lemey,et al.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time , 2013, Proceedings of the National Academy of Sciences.

[4]  Sarah Palmer,et al.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. , 2014, The lancet. HIV.

[5]  B. Korber,et al.  Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E , 2016, Science.

[6]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[7]  J. Mellors,et al.  HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo , 2015, Journal of Virology.

[8]  J. Ananworanich,et al.  Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. , 2015, AIDS patient care and STDs.

[9]  D. Havlir,et al.  The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. , 2013, The Journal of infectious diseases.

[10]  R. Gottardo,et al.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. , 2013, The Journal of infectious diseases.

[11]  C. Rouzioux,et al.  HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. , 2016, The lancet. HIV.

[12]  H. Hatano,et al.  Reduction of HIV Persistence Following Transplantation in HIV‐Infected Kidney Transplant Recipients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[14]  M. McCarter,et al.  CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue12 , 2007, The Journal of Immunology.

[15]  M. Cotton,et al.  HIV cure research in South Africa: a preliminary exploration of stakeholder perspectives , 2016, AIDS care.

[16]  Rebecca Hoh,et al.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. , 2015, The lancet. HIV.

[17]  D. Richman,et al.  Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. , 2014, JAMA pediatrics.

[18]  Jeffrey N. Martin,et al.  HIV antibody characterization as a method to quantify reservoir size during curative interventions. , 2014, The Journal of infectious diseases.

[19]  A. Tanuri,et al.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C&dgr;–NF-&kgr;B signaling , 2014, AIDS.

[20]  A. Fauci,et al.  An HIV cure: feasibility, discovery, and implementation. , 2014, JAMA.

[21]  M. Churchill,et al.  HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure research , 2014, Journal of NeuroVirology.

[22]  B. Berkhout,et al.  Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment , 2015, AIDS.

[23]  S. Lewin,et al.  Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. , 2015, AIDS.

[24]  M. Weinstein,et al.  HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? , 2014, PloS one.

[25]  Daniel I. S. Rosenbloom,et al.  Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. , 2015, The Journal of clinical investigation.

[26]  P. Volberding,et al.  Words matter: Discussing research towards an HIV cure in research and clinical contexts. , 2014, Journal of acquired immune deficiency syndromes.

[27]  J. Hoxie,et al.  Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy–treated macaques , 2015, Nature Methods.

[28]  G. Pantaleo,et al.  PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals , 2016, Nature Medicine.

[29]  R. Siliciano,et al.  Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient , 2013, PLoS pathogens.

[30]  J. Mascola,et al.  Activation and lysis of human CD4 cells latently infected with HIV-1 , 2015, Nature Communications.

[31]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[32]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[33]  S. Deeks,et al.  Immunologic strategies for HIV-1 remission and eradication , 2014, Science.

[34]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[35]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[36]  Eric Verdin,et al.  An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients , 2013, PLoS pathogens.

[37]  Carl June,et al.  Chemokine receptor 5 knockout strategies , 2011, Current opinion in HIV and AIDS.

[38]  M. Nussenzweig,et al.  Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice , 2014, Cell.

[39]  C. Rouzioux,et al.  A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control , 2015, AIDS.

[40]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[41]  R. Siliciano,et al.  Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies , 2013, PLoS pathogens.

[42]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[43]  M. Swanson,et al.  Generation of HIV Latency in Humanized BLT Mice , 2011, Journal of Virology.

[44]  S. Hughes,et al.  Specific HIV integration sites are linked to clonal expansion and persistence of infected cells , 2014, Science.

[45]  J. Mellors,et al.  Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[46]  M. Hudgens,et al.  Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART , 2014, PLoS pathogens.

[47]  Matthew S. Lewis,et al.  Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms , 2013, Science.

[48]  E. Rosenberg,et al.  HIV-1 persistence in CD4+ T cells with stem cell-like properties , 2014, Nature Medicine.

[49]  S. Lewin,et al.  Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy , 2016, AIDS.

[50]  Brendan B. Larsen,et al.  Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection , 2014, Science.

[51]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[52]  J. Tucker,et al.  Social and ethical implications of HIV cure research , 2014, AIDS.

[53]  R. Siliciano,et al.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.

[54]  D. Cooper,et al.  HIV DNA Subspecies Persist in both Activated and Resting Memory CD4+ T Cells during Antiretroviral Therapy , 2014, Journal of Virology.

[55]  G. Henderson,et al.  What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent , 2015, Journal of virus eradication.

[56]  R. Siliciano,et al.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. , 2008, Cell host & microbe.

[57]  L. Trautmann,et al.  The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency , 2015, mBio.

[58]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[59]  A. De Maria,et al.  Absence of HIV-1 after treatment cessation in an infant. , 2014, The New England journal of medicine.

[60]  Nancie M Archin,et al.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. , 2015, The Journal of infectious diseases.

[61]  J. Karn,et al.  Establishment of HIV Latency in Primary CD4+ Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction , 2010, Journal of Virology.

[62]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[63]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[64]  Baoshan Zhang,et al.  AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges , 2015, Nature.

[65]  Emily B Hanhauser,et al.  Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation , 2014, Annals of Internal Medicine.

[66]  Jack T Stapleton,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[67]  Z. Klase,et al.  Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. , 2014, Immunity.

[68]  Anthony R Cillo,et al.  Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy , 2014, Proceedings of the National Academy of Sciences.

[69]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[70]  G. Henderson.  The ethics of HIV "cure" research: what can we learn from consent forms? , 2015, AIDS research and human retroviruses.

[71]  L. Picker,et al.  A B cell follicle sanctuary permits persistent productive SIV infection in elite controllers , 2014, Nature Medicine.

[72]  J. Clements,et al.  A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads. , 2015, The Journal of infectious diseases.

[73]  O. Yang,et al.  In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells , 2012, PLoS pathogens.

[74]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[75]  S. Valente,et al.  Targeting HIV transcription: the quest for a functional cure. , 2015, Current topics in microbiology and immunology.

[76]  R. Walensky,et al.  The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis , 2015, Journal of virus eradication.

[77]  A. Haase,et al.  Macrophages sustain HIV replication in vivo independently of T cells. , 2016, The Journal of clinical investigation.

[78]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[79]  H. Kiem,et al.  Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. , 2010, The Journal of clinical investigation.

[80]  D. Irvine,et al.  Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes , 2014, PLoS pathogens.

[81]  P. Goulder,et al.  Immunity to HIV in Early Life , 2014, Front. Immunol..

[82]  J. Lifson,et al.  Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[83]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[84]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[85]  G. Pantaleo,et al.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.

[86]  王涛,et al.  联合国HIV／AIDS综合规划（UNAIDS） , 1996 .

[87]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[88]  T. Chun,et al.  Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir , 2014, Proceedings of the National Academy of Sciences.

[89]  Peter A. Newman,et al.  Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence , 2014, Expert review of vaccines.

[90]  C. Van Lint,et al.  Transcriptional activation and chromatin remodeling of the HIV‐1 promoter in response to histone acetylation. , 1996, The EMBO journal.

[91]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[92]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[93]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[94]  R. Siliciano,et al.  BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism , 2013, Cell cycle.

[95]  G. Alter,et al.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. , 2015, AIDS research and human retroviruses.

[96]  J. Delfraissy,et al.  Past, present and future: 30 years of HIV research , 2013, Nature Reviews Microbiology.

[97]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[98]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[99]  H. Liao,et al.  Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. , 2015, The Journal of clinical investigation.

[100]  P. Volberding,et al.  Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. , 2015, AIDS research and human retroviruses.

[101]  R. Lempicki,et al.  Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus , 2014, AIDS.

[102]  H. Schuitemaker,et al.  OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion , 2001, Journal of Clinical Immunology.

[103]  G. Yenokyan,et al.  Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[104]  Yang Shi,et al.  The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 , 2000, Journal of Virology.

[105]  A. Samri,et al.  Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. , 2015, The Journal of antimicrobial chemotherapy.

[106]  Suha M. Saleh,et al.  Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells , 2013, AIDS.

[107]  S. Hughes,et al.  Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo , 2016, Proceedings of the National Academy of Sciences.

[108]  O. Witte,et al.  Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells , 2015, Proceedings of the National Academy of Sciences.

[109]  V. Calvez,et al.  Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial , 2016, AIDS.

[110]  D. Hazuda,et al.  A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals , 2015, EBioMedicine.

[111]  J. Ananworanich,et al.  Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children , 2014, AIDS.

[112]  Fan Yang,et al.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection , 2014, Proceedings of the National Academy of Sciences.

[113]  Rebecca Hoh,et al.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. , 2013, The Journal of infectious diseases.

[114]  A. Perelson,et al.  Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection , 2012, Proceedings of the National Academy of Sciences.

[115]  Jinyan Liu,et al.  Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys , 2014, Nature.

[116]  Shiu-Lok Hu,et al.  Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. , 2013, Blood.

[117]  R. Siliciano,et al.  Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay , 2013, PLoS pathogens.

[118]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[119]  J. Lifson,et al.  Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. , 2015, The Journal of clinical investigation.

[120]  Jeffrey N. Martin,et al.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. , 2013, The Journal of infectious diseases.

[121]  J. Church.  Vectored Immunoprophylaxis Protects Humanized Mice From Mucosal HIV Transmission , 2014, Pediatrics.

[122]  M. Marsden,et al.  HIV Latency in the Humanized BLT Mouse , 2011, Journal of Virology.

[123]  J. Amon.  Dangerous medicines: Unproven AIDS cures and counterfeit antiretroviral drugs , 2008, Globalization and health.